Navigation Links
Curemark Presents at Springboard Enterprises Life Sciences Forum
Date:11/10/2009

RYE, N.Y., Nov. 10 /PRNewswire/ -- Curemark, LLC, a drug research and development company currently developing a treatment for autism, was one of 32 biotech companies headed by women selected to present at the Springboard Enterprises AllThingsLifeSciences 2009 forum, held recently in Silicon Valley, Madison, Wisconsin, and New York City. More than 100 companies from the U.S. and abroad applied to participate.

"The opportunity to present our science, discuss our progress and share ideas with the investors and biotech CEOs attending the Springboard Forum was an invaluable experience for us," said Dr. Joan Fallon, founder and CEO of Curemark. "We applaud the vision of Springboard founder Kay Koplovitz in conceiving these Forums as a way to support the growth of entrepreneurial ventures headed by women and help facilitate their ability to secure financing."

Curemark now is enrolling patients at 12 sites across the country in Phase III clinical trials for CM-AT, one of the first therapies targeted to address the underlying physiology of autism. CM-AT is based on research by Dr. Fallon that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein. The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function. The company announced in August that it had closed a $6.5 million Series A financing round.

Founded in 1999, Springboard Enterprises is a non-profit organization that facilitates access to the equity markets for women entrepreneurs. Springboard recruits, educates, showcases and supports high growth businesses led by women as they seek venture capital. At Springboard Forums, women entrepreneurs and CEOs pitch their emerging growth ventures to private equity investors, effectively fast-tracking the pipeline for venture capital financing. The 400 companies that have been selected to present at Springboard forums have raised over $4.5 billion in equity, grants and strategic investments.

About CUREMARK LLC

Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com.

Safe Harbor Statement

This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.

SOURCE Curemark, LLC


'/>"/>
SOURCE Curemark, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009
2. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
3. DIATHERIX Laboratories Presents at Homeland Security Conference
4. Sanofi Pasteur Presents Safety Data on Menactra(R) Vaccine Given to Infants at Infectious Disease Society Meeting
5. Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDFs 20th World Diabetes Congress
6. Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31, 2009
7. AlphaHelix Presents AmpXpress(TM) at the BIOTECHNICA Show
8. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
9. InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
10. NovaBay(R) Presents Data Confirming Its Aganocide(R) Compounds Are Effective In Killing Bacteria That Have Developed Multidrug-Resistance
11. Novexel Presents 16 Posters and one Slide Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Meeting in San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... The report "Cryocooler Market by ... (Technical Support, Product Repairs & Refurbishment, Preventive Maintenance, and ... 2022", published by MarketsandMarkets, the global market is expected ... a CAGR of 7.29% between 2016 and 2022. ... Figures spread through 159 Pages and in-depth TOC on ...
(Date:4/28/2016)... Q BioMed Inc. (OTCQB:QBIO), ...  was featured in an article he wrote on ... To Tread: http://www.lifescienceleader.com/doc/accelerators-enter-when-vcs-fear-to-tread-0001 ... an essential business journal for life science executives ... Big Pharmas. Their content is designed to inform ...
(Date:4/28/2016)... ... April 28, 2016 , ... Connecticut Innovations (CI), ... today announced the launch of VentureClash , a $5 million global investment ... “VentureClash looks to attract the best early-stage companies here in Connecticut, around the ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... will deliver a talk on its first-in-class technologies for tissue stem cell ... Meeting on RNAiMicroRNA Biology to Reprogramming & CRISPR-based Genome Engineering in Burlington, ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/26/2016)... LONDON , April 26, 2016 ... EdgeVerve Systems, a product subsidiary of Infosys (NYSE: ... a partnership to integrate the Onegini mobile security ... (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The ... enhanced security to access and transact across channels. ...
Breaking Biology News(10 mins):